These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 27279380)

  • 1. Effectiveness of intensification therapies in Danes with Type 2 diabetes who use basal insulin: a population-based study.
    Thomsen RW; Baggesen LM; Søgaard M; Pedersen L; Nørrelund H; Buhl ES; Haase CL; Johnsen SP
    Diabet Med; 2017 Feb; 34(2):213-222. PubMed ID: 27279380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetes.
    Thomsen RW; Baggesen LM; Søgaard M; Pedersen L; Nørrelund H; Buhl ES; Haase CL; Johnsen SP
    Diabetologia; 2015 Oct; 58(10):2247-53. PubMed ID: 26277380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of delaying treatment intensification with a glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes uncontrolled on basal insulin: A longitudinal study of a US administrative claims database.
    Tong L; Pan C; Wang H; Bertolini M; Lew E; Meneghini LF
    Diabetes Obes Metab; 2018 Apr; 20(4):831-839. PubMed ID: 29119712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term sustainability of glycaemic achievements with second-line antidiabetic therapies in patients with type 2 diabetes: A real-world study.
    Montvida O; Shaw JE; Blonde L; Paul SK
    Diabetes Obes Metab; 2018 Jul; 20(7):1722-1731. PubMed ID: 29536608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensification patterns and the probability of HbA
    Pantalone KM; Misra-Hebert AD; Hobbs TM; Ji X; Kong SX; Milinovich A; Weng W; Bauman JM; Ganguly R; Burguera B; Kattan MW; Zimmerman RS
    Diabet Med; 2020 Jul; 37(7):1114-1124. PubMed ID: 30653705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin.
    Khunti K; Nikolajsen A; Thorsted BL; Andersen M; Davies MJ; Paul SK
    Diabetes Obes Metab; 2016 Apr; 18(4):401-9. PubMed ID: 26743666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial.
    Miser WF; Arakaki R; Jiang H; Scism-Bacon J; Anderson PW; Fahrbach JL
    Clin Ther; 2010 May; 32(5):896-908. PubMed ID: 20685497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addition of or switch to insulin therapy in people treated with glucagon-like peptide-1 receptor agonists: A real-world study in 66 583 patients.
    Montvida O; Klein K; Kumar S; Khunti K; Paul SK
    Diabetes Obes Metab; 2017 Jan; 19(1):108-117. PubMed ID: 27629433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Slow Titration and Delayed Intensification of Basal Insulin Among Patients with Type 2 Diabetes.
    Mocarski M; Yeaw J; Divino V; DeKoven M; Guerrero G; Langer J; Thorsted BL
    J Manag Care Spec Pharm; 2018 Apr; 24(4):390-400. PubMed ID: 29406841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour.
    de Boer SA; Lefrandt JD; Petersen JF; Boersma HH; Mulder DJ; Hoogenberg K
    Int J Clin Pharm; 2016 Feb; 38(1):144-51. PubMed ID: 26597956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial.
    Rosenstock J; Guerci B; Hanefeld M; Gentile S; Aronson R; Tinahones FJ; Roy-Duval C; Souhami E; Wardecki M; Ye J; Perfetti R; Heller S;
    Diabetes Care; 2016 Aug; 39(8):1318-28. PubMed ID: 27222510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis.
    Huthmacher JA; Meier JJ; Nauck MA
    Diabetes Care; 2020 Sep; 43(9):2303-2312. PubMed ID: 32910778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
    Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. De-intensification of basal-bolus insulin regimen after initiation of a GLP-1 RA improves glycaemic control and promotes weight loss in subjects with type 2 diabetes.
    Falcetta P; Nicolì F; Citro F; Ciccarone A; Garofolo M; Del Prato S; Bianchi C
    Acta Diabetol; 2023 Jan; 60(1):53-60. PubMed ID: 36166172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal changes in glycated haemoglobin following treatment intensification after inadequate response to two oral antidiabetic agents in patients with type 2 diabetes.
    Kim K; Unni S; Brixner DI; Thomas SM; Olsen CJ; Sterling KL; Mitchell M; McAdam-Marx C
    Diabetes Obes Metab; 2019 Jul; 21(7):1725-1733. PubMed ID: 30848039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment intensification for patients with type 2 diabetes and poor glycaemic control.
    Fu AZ; Sheehan JJ
    Diabetes Obes Metab; 2016 Sep; 18(9):892-8. PubMed ID: 27160505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study.
    Guja C; Frías JP; Somogyi A; Jabbour S; Wang H; Hardy E; Rosenstock J
    Diabetes Obes Metab; 2018 Jul; 20(7):1602-1614. PubMed ID: 29473704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Free and fixed-ratio combinations of basal insulin and GLP-1 receptor agonists versus basal insulin intensification in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Maiorino MI; Chiodini P; Bellastella G; Scappaticcio L; Longo M; Esposito K; Giugliano D
    Diabetes Obes Metab; 2018 Sep; 20(9):2309-2313. PubMed ID: 29732679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients.
    Abd El Aziz MS; Kahle M; Meier JJ; Nauck MA
    Diabetes Obes Metab; 2017 Feb; 19(2):216-227. PubMed ID: 27717195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin and Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Maiorino MI; Chiodini P; Bellastella G; Capuano A; Esposito K; Giugliano D
    Diabetes Care; 2017 Apr; 40(4):614-624. PubMed ID: 28325801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.